The citizens of Huizhou city have selected drugs in negotiations with high quality and low price

Text, photo/ Yangcheng Evening News all-media reporter Li Haichan correspondent Long Liu Zheng Haiyan

"I was the first patient to enjoy dalytoliumab health insurance, which greatly reduced my medication burden and I was more confident about my recovery!" Aunt Gao Gao (pseudonym), a 77-year-old patient who is hospitalized in the Department of Hematology of the First People's Hospital of Huizhou City, is grateful to the doctor. With the official implementation of the latest medical insurance catalogue on January 1, 2022, patients with relapsed and refractory multiple myeloma (MM) who visited the Department of Hematology of the First People's Hospital of Huizhou City have enjoyed the medical insurance reimbursement policy for treatment drugs with cross-era significance on the first working day of the new year.

Huizhou patients enjoyed the medical insurance reimbursement policy for therapeutic drugs

Multiple myeloma is a common hematologic malignancy, the second largest hematologic malignancy after lymphoma, characterized by abnormal hyperplasia of bone marrow plasma cells, more common in the elderly population. Patients with related symptoms, such as: increased blood calcium, renal impairment, anemia, bone disease, infection and hyperviscosity, etc., it is recommended to go to the hospital for examination as soon as possible, so as to achieve early detection and early treatment. With the acceleration of the aging process in China, the incidence of MM will continue to increase.

As the world's first and only approved cd38 fully humanized monoclonal antibody in China, darrituliumab has a unique dual mechanism of targeted immunity, which directly hits the key to MM treatment, and the treatment plan containing dalytoyuzumab has been recommended by multiple authoritative guidelines at home and abroad such as NCCN guidelines and ESMO guidelines for the full-line treatment of MM patients. Medical insurance reimbursement will be officially implemented from January 1, 2022.

Two years ago, after experiencing a sudden lumbar pain, Aunt Gao immediately went to the First People's Hospital of Huizhou City for treatment and was diagnosed with myeloma.

In early December 2021, after a thorough examination, doctors decided that a more effective treatment regimen would need to be changed due to changes in the condition. However, due to the high price of darrituliumab injection, an innovative drug for the treatment of MM, in the case of non-medical insurance payments, the cost of treatment in a month is as high as about 80,000, and Aunt Gao's family is really difficult to support the replacement of new treatment plans.

The turning point came on December 3, 2021, when Aunt Gao's son learned from the good news that darrituliumab injection had been officially included in the scope of medical insurance reimbursement. Aunt Gao can finally use and afford to use innovative drugs! On the first working day of the new year, Aunt Gao used a treatment plan containing darrituliumab injection combined with chemotherapy in the hospital, and became the first patient in Huizhou to enjoy this medical insurance policy.

In order to protect the treatment needs of patients and reduce the economic burden of patients, the Department of Hematology of the First People's Hospital of Huizhou City also prescribed this innovative medical insurance drug for MM patients for the first time, so that MM patients can enjoy high-quality and inexpensive innovative drugs as soon as possible, benefit from innovative therapies in a timely manner, and have the hope of survival.

Source | Yangcheng Evening News Yangcheng Pie

Editor-in-charge | He Quansheng